UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/373,230	08/12/1999	HARUKI OKMURA	OKAMURA=2E	2359
	7590 07/14/200 D NEIMARK, P.L.L.C	EXAMINER		
624 NINTH ST		JIANG, DONG		
SUITE 300 WASHINGTON, DC 20001-5303			ART UNIT	PAPER NUMBER
			1646	
			MAIL DATE	DELIVERY MODE
			07/14/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)					
Office Action Commence	09/373,230	OKMURA ET AL.					
Office Action Summary	Examiner	Art Unit					
	DONG JIANG	1646					
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address					
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be time will apply and will expire SIX (6) MONTHS from cause the application to become ABANDONEI	l. lely filed the mailing date of this communication. (35 U.S.C. § 133).					
Status							
1) Responsive to communication(s) filed on 16 Ap	oril 2009						
<i>7</i>	,—						
,—	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims							
4)⊠ Claim(s) <u>26 and 27</u> is/are pending in the application.							
	4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.							
6)⊠ Claim(s) <u></u> is/are allowed. 6)⊠ Claim(s) <u>26 and 27</u> is/are rejected.							
7) Claim(s) is/are objected to.							
· · · · · · · · · · · · · · · · · · ·	8) Claim(s) is/are objected to: 8 Claim(s) are subject to restriction and/or election requirement.						
Application Papers							
9) The specification is objected to by the Examiner.							
10) ☐ The drawing(s) filed on is/are: a) ☐ acce	· · · · · · · · · · · · · · · · · · ·						
Applicant may not request that any objection to the							
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).							
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
Priority under 35 U.S.C. § 119							
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 							
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	te					

Art Unit: 1646

DETAILED OFFICE ACTION

Applicant's amendment filed on 16 April 2009 is acknowledged and entered. Following the amendment, claims 18, 19, 24, 25 and 28 are canceled, and claim 26 is amended.

Currently, claims 26 and 27 are pending and under consideration.

Withdrawal of Objections and Rejections:

All objections and rejections of claims 18, 19, 24, 25 and 28 are most as the applicant has canceled the claims.

Double Patenting Rejections:

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 26 and 27 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1 and 4 of U.S. Patent No. 6,476,197 B1. Although the conflicting claims are not identical, they are not patentably distinct from each other for the following reasons.

Application/Control Number: 09/373,230 Page 3

Art Unit: 1646

Claim 1 of the patent is directed to an artificial polypeptide derived from a wild-type polypeptide comprising either SEQ ID NO:4 or SEQ ID NO:5, wherein the artificial polypeptide can be the amino acid sequence of SEQ ID NO:4 or 5 in which one or more cysteine residues are replaced with an amino acid residues(s) other than cysteine (part (ii)). Claim 4 of the patent is directed to a pharmaceutical composition of the artificial polypeptide of claim 1. SEQ ID NO:5 of the patent is 100% identical to the present SEQ ID NO:2. Thus, the artificial polypeptide of claim 1 of the patent reads on the variant of SEQ ID NO:2 of the present invention (claim 26, part (i)), and represents a species of the variant genus of SEQ ID NO:2, which has "one or two amino acids in SEQ ID NO:2 are replaced with other amino acids". It is well established that a species of a claimed invention renders the genus obvious. *In re Schaumann*, 572 F.2d 312, 197 USPQ 5 (CCPA 1978). Therefore, the species claimed in claims 1 and 4 of the '197 patent renders instant claims 26 and 27 obvious, and the conflicting claims not patentably distinct from each other even though the scope of the inventions is different.

Conclusion:

No claim is allowable.

Application/Control Number: 09/373,230 Page 4

Art Unit: 1646

Advisory Information:

Any inquiry concerning this communication should be directed to Dong Jiang whose telephone number is 571-272-0872. The examiner can normally be reached on Monday - Friday from 9:30 AM to 7:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Nickol, can be reached on 571-272-0835. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Dong Jiang/ Primary Examiner, Art Unit 1646 7/10/09